A Phase II Open-Label Study to Investigate the Effects of CK-1827452 Injection on Ventricular Performance, Myocardial Oxygen Consumption, and Myocardial Efficiency in Patients With Heart Failure and Left Ventricular Systolic Dysfunction.

Trial Profile

A Phase II Open-Label Study to Investigate the Effects of CK-1827452 Injection on Ventricular Performance, Myocardial Oxygen Consumption, and Myocardial Efficiency in Patients With Heart Failure and Left Ventricular Systolic Dysfunction.

Discontinued
Phase of Trial: Phase II

Latest Information Update: 02 Nov 2015

At a glance

  • Drugs Omecamtiv mecarbil (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Sponsors Cytokinetics
  • Most Recent Events

    • 18 Dec 2008 Results are expected in 2009.
    • 25 Sep 2008 Trial design presented at the Annual Meeting of the Heart Failure Society of America in Sep 2008.
    • 05 Sep 2008 Status changed from planning to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top